Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380068 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT00380068 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 224 participants.
The verdict
NCT00380068, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380068
The ClinicalTrials.gov registry entry for NCT00380068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00380068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380068 about?
NCT00380068 is a clinical study titled "Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension". The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertens...
What is the current status of trial NCT00380068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2006-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00380068?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00380068?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.